The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | T-cell therapy: successes and unmet needs
David Maloney
• 25 Aug 2017
David Maloney, MD, PhD from the Seattle Cancer Care Alliance, Seattle, WA discusses the patients for whom T-cell therapy demonstrates high efficacy. Dr Maloney also describes where the greatest unmet needs lie. This interview was recorded at the 2017 European Hematology Association (EHA) annual congress held in Madrid, Spain.
